menu
    • menu
    [{"orgOrder":0,"company":"JJP Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JJP Biologics to Execute First-in-Human Trial of mAb JJP-1212 for Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"JJP-1212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"JJP Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JJP Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JJP Biologics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by JJP Biologics

    Menu

    JJP Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JJP Biologics

                            Poland arrow
                            FNCE 2024
                            Not Confirmed

                            JJP Biologics

                            Poland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JJP-1212

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            JJP Biologics to Execute First-in-Human Trial of mAb JJP-1212 for Inflammation

                            Details : JJP-1212, their potential first-in-class CD89 inhibitor, which is being evaluated in the early-stage clinical trial studies for the treatment of various IgA-mediated autoimmune- and fibrotic diseases.

                            Brand Name : JJP-1212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 29, 2024

                            Lead Product(s) : JJP-1212

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth